Lars Noah

Education

J.D., Harvard University (magna cum laude)
B.A., Harvard University (magna cum laude)

Expertise

Constitutional Law, Medical Technology, Public Health Law, S.T.E.M. subjects, Tort Law

Courses

Medical Technology
Public Health Law
Torts

Publications

Books

• LAW AND THE PUBLIC’S HEALTH: CASES, CONTROVERSIES & COVID-19 (Carolina Academic Press 2023).
• LAW, MEDICINE, AND MEDICAL TECHNOLOGY: CASES & MATERIALS (Foundation Press 5th ed. 2022).
• LAW, MEDICINE, AND MEDICAL TECHNOLOGY: CASES & MATERIALS (Foundation Press 4th ed. 2017).
• LAW, MEDICINE, AND MEDICAL TECHNOLOGY: CASES & MATERIALS (Foundation Press 3d ed. 2012).
• LAW, MEDICINE, AND MEDICAL TECHNOLOGY: CASES & MATERIALS (Foundation Press 2d ed. 2007).
• LAW, MEDICINE, AND MEDICAL TECHNOLOGY: CASES & MATERIALS (Foundation Press 2002).

Selected Articles

• Transactional Governance and the Weaponization of Executive Orders, 2026 Mich. St. L. Rev. (forthcoming Apr. 2026).
• “Market Shift Liability” for Generic Drugs: Market Share Theory’s Eccentric New Cousin, 13 Tex. A&M L. Rev. (forthcoming Apr. 2026).
• Compelled Contraception, 128 W. Va. L. Rev. (forthcoming Nov. 2025).
• Medication Abortion and the Mails: The Ghost of Anthony Comstock Rides Again?, 41 Ga. St. U. L. Rev. 913 (2025).
• Flaws in the Preemption Defense to Liability Claims Against Generic Drug Manufacturers, 79 U. Miami L. Rev. 431 (2025).
• Preempting Red State Restrictions on the Use of FDA-Approved Drugs in Gender-Affirming Care?, 2024 Utah L. Rev. 833 (2024).
• Eliding Consent in the Case of Pandemic Countermeasures Authorized for Emergency Use, 58 Ind. L. Rev. 83 (2024).
• “Major Questions” Malarkey: An Arbitrary and Capricious New Doctrine for Vetoing Controversial Agency Rules, 98 St. John’s L. Rev. 597 (2024).
• Does Federal Preemption Inoculate Us Against the Alarming Prospect of State Vaccine Bans?, 100 Ind. L.J. Supp. 1 (2024).
• Must Courts Recalibrate Tort Law Governing Firearms in Light of the Second Amendment?, 92 U. Cin. L. Rev. 412 (2023).
• Listening to Mifepristone, 80 N.Y.U. Ann. Surv. Am. L. 33 (2023).
• Time to Bite the Bullet?: How an Emboldened FDA Could Take Aim at the Firearms Industry, 53 Conn. L. Rev. 787 (2022).
• Confronting the Inevitability of Diagnostic Uncertainty Across Multiple Legal Domains, in Diagnoses Without Names 59 (2022).
• Censorship Is So Last Century: Therapeutic Products, Propaganda, and Compelled Speech, 66 St. Louis U. L.J. 79 (2021).
• State Regulatory Responses to the Prescription Opioid Crisis: Too Much to Bear?, 124 Dick. L. Rev. 633 (2020).
• Banning Off-Label Drug Promotion Offends the U.S. Constitution: Making the Strongest Case, 83 Alb. L. Rev. 301 (2020).
• Does the U.S. Constitution Constrain State Products Liability Doctrine?, 92 Temp. L. Rev. 189 (2019).
• Federal Regulatory Responses to the Prescription Opioid Crisis: Too Little, Too Late?, 2019 Utah L. Rev. 757 (2019).
• Giving Personal Injury Attorneys Who Run Misleading Drug Ads a Dose of Their Own Medicine, 2019 U. Ill. L. Rev. 791 (2019).
• Doctors on the Take: Aligning Tort Law to Address Drug Company Payments to Prescribers, 66 Buff. L. Rev. 855 (2018).
• Reversal of Fortune: Moving Pharmaceuticals from Over-the-Counter to Prescription Status?, 63 Vill. L. Rev. 355 (2018).
• “Go Sue Yourself!” Imagining Intrapersonal Liability for Negligently Self-Inflicted Harms, 70 Fla. L. Rev. 649 (2018).
• When Constitutional Tailoring Demands the Impossible: Unrealistic Scrutiny of Agencies?, 85 Geo. Wash. L. Rev. 1462 (2017).
• State Affronts to Federal Primacy in the Licensure of Pharmaceutical Products, 2016 Mich. St. L. Rev. 1 (2016).
• Growing Organs in the Lab: Tissue Engineers Confront Institutional “Immune” Responses, 55 Jurimetrics J. 297 (2015).
• Product Hopping 2.0: Getting the FDA to Yank Your Original License Beats Stacking Patents, 19 Marq. Intell. Prop. L. Rev. 161 (2015).
• Governance by the Backdoor: Administrative Law(lessness?) at the FDA, 93 Neb. L. Rev. 89 (2014).
• Permission to Speak Freely?, 162 U. Pa. L. Rev. Online 248 (2014).
• Genetic Modification and Food Irradiation: Are Those Strictly on a Need-to-Know Basis?, 118 Penn. St. L. Rev. 759 (2014).
• Turn the Beat Around?: Deactivating Implanted Cardiac-Assist Devices, 39 Wm. Mitchell L. Rev. 1229 (2013).
• Whatever Happened to the “Frankenfish”?: The FDA’s Foot-Dragging on Transgenic Salmon, 65 Me. L. Rev. 606 (2013).
• Truth or Consequences?: Commercial Free Speech vs. Public Health Promotion (at the FDA), 21 Health Matrix 31 (2011).
• Coerced Participation in Clinical Trials: Conscripting Human Research Subjects, 62 Admin. L. Rev. 329 (2010).
• Adding Insult to Injury: Paying for Harms Caused by a Competitor’s Copycat Product, 45 Tort Trial & Ins. Prac. L.J. 673 (2010).
• Comfortably Numb: Medicalizing (and Mitigating) Pain-and-Suffering Damages, 42 U. Mich. J.L. Reform 431 (2009).
• This Is Your Products Liability Restatement on Drugs, 74 Brook. L. Rev. 839 (2009).
• Platitudes About “Product Stewardship” in Torts: Continuing Drug Research and Education, 15 Mich. Tel. & Tech. L. Rev. 359 (2009).
• The Little Agency That Could (Act with Indifference to Constitutional and Statutory Strictures), 93 Cornell L. Rev. 901 (2008).
• Too High a Price for Some Drugs?: The FDA Burdens Reproductive Choice, 44 San Diego L. Rev. 231 (2007).
• Treat Yourself: Is Self-Medication the Prescription for What Ails American Health Care?, 19 Harv. J.L. & Tech. 359 (2006).
• Managing Biotechnology’s [R]evolution: Has Guarded Enthusiasm Become Benign Neglect?, 11 Va. J.L. & Tech. 4 (2006).
• An Inventory of Mathematical Blunders in Applying the Loss-of-a-Chance Doctrine, 24 Rev. Litig. 369 (2005).
• Medical Education and Malpractice: What’s the Connection?, 15 Health Matrix 149 (2005).
• Ambivalent Commitments to Federalism in Controlling the Practice of Medicine, 53 U. Kan. L. Rev. 149 (2004).
• A Postmodernist Take on the Human Embryo Research Debate, 36 Conn. L. Rev. 1133 (2004).
• Deputizing Institutional Review Boards to Police (Audit?) Biomedical Research, 25 J. Legal Med. 267 (2004).
• Letter, Trends in Assisted Reproductive Technology, 351 New Eng. J. Med. 398 (2004).
• Assisted Reproductive Technologies and the Pitfalls of Unregulated Biomedical Innovation, 55 Fla. L. Rev. 603 (2003).
• Challenges in the Federal Regulation of Pain Management Technologies, 31 J.L. Med. & Ethics 55 (2003).
• Triage in the Nation’s Medicine Cabinet: The Puzzling Scarcity of Vaccines and Other Drugs, 54 S.C. L. Rev. 741 (2003).
• Letter, Pharmacogenetics, 348 New Eng. J. Med. 2042 (2003).
• The Coming Pharmacogenomics Revolution: Tailoring Drugs to Fit Patients’ Genetic Profiles, 43 Jurimetrics J. 1 (2002).
• Informed Consent and the Elusive Dichotomy Between Standard and Experimental Therapy, 28 Am. J.L. & Med. 361 (2002).
• Medicine’s Epistemology: Mapping the Haphazard Diffusion of Knowledge in the Biomedical Community, 44 Ariz. L. Rev. 373 (2002).
• Letter, Attorney General’s Intrusion into Clinical Practice, 346 New Eng. J. Med. 1918 (2002).
• Letter, Standards for Medical Expert Testimony, 288 JAMA 2971 (2002).
• Civil Jury Nullification, 86 Iowa L. Rev. 1601 (2001).
• A Miscarriage in the Drug Approval Process?: Mifepristone Embroils the FDA in Abortion Politics, 36 Wake Forest L. Rev. 571 (2001).
• Rewarding Regulatory Compliance: The Pursuit of Symmetry in Products Liability, 88 Geo. L.J. 2147 (2000).
• Interpreting Agency Enabling Acts: Misplaced Metaphors in Administrative Law, 41 Wm. & Mary L. Rev. 1463 (2000).
• Scientific “Republicanism”: Expert Peer Review and the Quest for Regulatory Deliberation, 49 Emory L.J. 1033 (2000).
• Divining Regulatory Intent: The Place for a “Legislative History” of Agency Rules, 51 Hastings L.J. 255 (2000).
• What’s Wrong with “Constitutionalizing Food and Drug Law”?, 75 Tul. L. Rev. 137 (2000).
• Peer Review and Regulatory Reform, 30 Envtl. L. Rep. 10,606 (2000).
• Pigeonholing Illness: Medical Diagnosis as a Legal Construct, 50 Hastings L.J. 241 (1999).
• Doubts About Direct Final Rulemaking, 51 Admin. L. Rev. 401 (1999).
• The Executive Line Item Veto and the Judicial Power to Sever: What’s the Difference?, 56 Wash. & Lee L. Rev. 235 (1999).
• Starting from Scratch?: Reinventing the Food Additive Approval Process, 78 B.U. L. Rev. 329 (1998).
• Sanctifying Scientific Peer Review: Publication as a Proxy for Regulatory Decisionmaking, 59 U. Pitt. L. Rev. 677 (1998).
• Authors, Publishers, and Products Liability: Remedies for Defective Information in Books, 77 Or. L. Rev. 1195 (1998).
• Regulating Cigarettes: (Non)sense and Sensibility, 22 S. Ill. U. L.J. 677 (1998).
• Administrative Arm-Twisting in the Shadow of Congressional Delegations of Authority, 1997 Wis. L. Rev. 873 (1997).
• Advertising Prescription Drugs to Consumers: Assessing the Regulatory and Liability Issues, 32 Ga. L. Rev. 141 (1997).
• The FDA’s New Policy on Guidelines: Having Your Cake and Eating It Too, 47 Cath. U. L. Rev. 113 (1997).
• NAFTA’s Impact on the Trade in Pharmaceuticals, 33 Hous. L. Rev. 1293 (1997).
• Reconceptualizing Federal Preemption of Tort Claims as the Government Standards Defense, 37 Wm. & Mary L. Rev. 903 (1996).
• Nicotine Withdrawal: Assessing the FDA’s Effort to Regulate Tobacco Products, 48 Ala. L. Rev. 1 (1996).
• Sham Petitioning as a Threat to the Integrity of the Regulatory Process, 74 N.C. L. Rev. 1 (1995).
• The Imperative to Warn: Disentangling the “Right to Know” from the “Need to Know” About Consumer Product Hazards, 11 Yale J. on Reg. 293 (1994).
• Constraints on the Off-Label Uses of Prescription Drug Products, 16 J. Prods. & Toxics Liab. 139 (1994).
• Amplification of Federal Preemption in Medical Device Cases, 49 Food & Drug L.J. 183 (1994).
• Death of a Salesman: To What Extent Can the FDA Regulate Promotional Statements?, 47 Food & Drug L.J. 309 (1992).
• Note, The Politics of En Banc Review, 102 Harv. L. Rev. 864 (1989).